Kyntra Bio (NASDAQ:KYNB) Given “Buy” Rating at HC Wainwright

Kyntra Bio (NASDAQ:KYNB)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $43.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 452.70% from the stock’s current price.

Other analysts also recently issued reports about the company. Weiss Ratings upgraded Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 14th. Oppenheimer began coverage on Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Rodman & Renshaw began coverage on shares of Kyntra Bio in a research report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.00.

Kyntra Bio Price Performance

Shares of NASDAQ:KYNB opened at $7.78 on Tuesday. Kyntra Bio has a 1 year low of $6.32 and a 1 year high of $12.60. The stock has a market capitalization of $31.51 million, a price-to-earnings ratio of 0.17 and a beta of 1.02. The company’s 50 day simple moving average is $7.27 and its 200 day simple moving average is $7.13.

Institutional Investors Weigh In On Kyntra Bio

A hedge fund recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC acquired a new position in Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned 0.68% of Kyntra Bio at the end of the most recent quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.